Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

The production of cell and gene therapies (CGTs) requires many steps, and each one determines the quality of the final product, especially its patient safety and efficacy. The key technologies used in ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

Akadeum Life Sciences, the leader in buoyant microbubble cell separation, today announced that its Chief Executive Officer Brandon McNaughton, PhD, will present at Biotech Showcase (TM) 2026 in San ...

RADNOR, PA & PHILADELPHIA, PA — Avantor, Inc. (NYSE: AVTR) has entered into a strategic partnership with BlueWhale Bio, a commercial-stage biotechnology firm focused on improving immune cell therapy ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

T cells play a big role in bringing cell and gene therapies to patients. Despite this clinical potential, scientists developing T cell therapies such as chimeric antigen receptor (CAR)-T cells, ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...